Home・Aktien・Editas Medicine Inc
Search

Editas Medicine Inc

Geschlossen

BrancheGesundheitswesen

2.84 -3.4

Buy

Kursupdate 12. Aug. 2026, 19:59 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.81

Max

3.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

6.8M

-18M

Verkäufe

9.1M

12M

EPS

-0.15

Gewinnspanne

-153.322

Angestellte

87

EBITDA

3.9M

-20M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+171.19% upside

Dividenden

By Acuity

Nächstes Ergebnis

9. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

25M

432M

Vorheriger Eröffnungskurs

6.24

Vorheriger Schlusskurs

2.84

Nachrichtenstimmung

By Acuity

63%

37%

279 / 340 Ranking in Healthcare

Editas Medicine Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Aug. 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

Lesen

10. Aug. 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

Lesen

7. Aug. 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

Lesen

6. Aug. 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

Lesen

5. Aug. 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

Lesen

31. Juli 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

Lesen

30. Juli 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

Lesen

29. Juli 2026, 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

Lesen

28. Juli 2026, 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

Lesen

27. Juli 2026, 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

Lesen

24. Juli 2026, 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

Lesen

22. Juli 2026, 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

Lesen

21. Juli 2026, 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Lesen

Peer-Vergleich

Kursveränderung

Editas Medicine Inc Prognose

Kursziel

By TipRanks

171.19% Vorteil

12-Monats-Prognose

Durchschnitt 8 USD  171.19%

Hoch 15 USD

Tief 4 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Editas Medicine Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

4

Buy

1

Halten

1

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Editas Medicine Inc – Dist abgegeben haben.

Stimmung

By Acuity

279 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

1,220.22

↑ +0.53%

JNJ

Johnson and Johnson

260.64

↑ +0.52%

ABBV

AbbVie Inc

248.19

↓-0.64%

UNH

UnitedHealth Group Inc

405.49

↑ +0.92%

MRK

Merck & Co Inc.

132.94

↑ +2.03%
help-icon Live chat